$CMPS
COMPASS Pathways plc

2023 Q4 Form 10-Q Financial Statement

#000162828023036170 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.192M $10.26M
YoY Change -10.1% -11.24%
% of Gross Profit
Research & Development $27.14M $21.53M
YoY Change 37.11% 54.01%
% of Gross Profit
Depreciation & Amortization -$102.0K $180.0K
YoY Change -206.25% 80.0%
% of Gross Profit
Operating Expenses $36.33M $34.06M
YoY Change 21.03% 33.39%
Operating Profit -$34.06M
YoY Change 33.39%
Interest Expense $498.0K $1.080M
YoY Change -113.97% -1.46%
% of Operating Profit
Other Income/Expense, Net $5.769M $735.0K
YoY Change 17.18% -89.91%
Pretax Income -$32.14M -$33.33M
YoY Change 4.23% 82.6%
Income Tax $394.0K $62.00K
% Of Pretax Income
Net Earnings -$32.53M -$33.39M
YoY Change 5.19% 81.75%
Net Earnings / Revenue
Basic Earnings Per Share -$0.67
Diluted Earnings Per Share -$0.52 -$0.67
COMMON SHARES
Basic Shares Outstanding 61.90M shares 45.78M shares
Diluted Shares Outstanding 49.63M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.2M $248.0M
YoY Change 53.76% 43.29%
Cash & Equivalents $220.2M $248.0M
Short-Term Investments
Other Short-Term Assets $1.895M $2.075M
YoY Change 100.53% 63.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $261.3M $284.8M
YoY Change 36.34% 30.38%
LONG-TERM ASSETS
Property, Plant & Equipment $423.0K $309.0K
YoY Change -31.44% -44.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $469.0K $500.0K
YoY Change 0.0% 15.74%
Other Assets $7.049M $5.878M
YoY Change 2055.66% 1865.89%
Total Long-Term Assets $14.69M $14.23M
YoY Change 160.34% 134.42%
TOTAL ASSETS
Total Short-Term Assets $261.3M $284.8M
Total Long-Term Assets $14.69M $14.23M
Total Assets $276.0M $299.0M
YoY Change 39.89% 33.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.892M $4.248M
YoY Change 23.76% -78.64%
Accrued Expenses $12.69M $9.900M
YoY Change 24.64% 11.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.60M $15.35M
YoY Change 25.7% -48.02%
LONG-TERM LIABILITIES
Long-Term Debt $28.76M $28.40M
YoY Change
Other Long-Term Liabilities $1.882M $2.000M
YoY Change 350.24% 370.59%
Total Long-Term Liabilities $30.64M $30.40M
YoY Change 7229.9% 7052.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.60M $15.35M
Total Long-Term Liabilities $30.64M $30.40M
Total Liabilities $50.24M $45.78M
YoY Change 213.74% 52.81%
SHAREHOLDERS EQUITY
Retained Earnings -$379.6M -$347.1M
YoY Change 45.36% 50.77%
Common Stock $635.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $225.7M $253.3M
YoY Change
Total Liabilities & Shareholders Equity $276.0M $299.0M
YoY Change 39.89% 33.19%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$32.53M -$33.39M
YoY Change 5.19% 81.75%
Depreciation, Depletion And Amortization -$102.0K $180.0K
YoY Change -206.25% 80.0%
Cash From Operating Activities -$27.78M -$17.05M
YoY Change -38.67% -10.36%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K $20.00K
YoY Change -103.74% 300.0%
Acquisitions
YoY Change
Other Investing Activities $2.000K $0.00
YoY Change
Cash From Investing Activities -$4.000K -$10.00K
YoY Change -96.26% -300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.00K 116.8M
YoY Change -93.58% -11678100.0%
NET CHANGE
Cash From Operating Activities -27.78M -17.05M
Cash From Investing Activities -4.000K -10.00K
Cash From Financing Activities 41.00K 116.8M
Net Change In Cash -27.74M 99.72M
YoY Change -38.04% -624.37%
FREE CASH FLOW
Cash From Operating Activities -$27.78M -$17.05M
Capital Expenditures -$4.000K $20.00K
Free Cash Flow -$27.78M -$17.07M
YoY Change -38.83% -10.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
469000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
469000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
617000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4165000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2006000 usd
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3406000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2224000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5878000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1510000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15350000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15596000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
28431000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1997000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
418000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
45778000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
16014000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34062000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
25536000 usd
us-gaap Operating Expenses
OperatingExpenses
98514000 usd
us-gaap Operating Expenses
OperatingExpenses
78212000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34062000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25536000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-98514000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-78212000 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1127000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
309000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000 usd
CY2023Q3 us-gaap Assets
Assets
299033000 usd
CY2022Q4 us-gaap Assets
Assets
197294000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4248000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4761000 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8998000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9325000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2104000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
617165000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458825000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17466000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16867000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347078000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261146000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
253255000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
181280000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299033000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
197294000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21526000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13977000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60379000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45259000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12536000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11559000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38135000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32953000 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3206000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2463000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3580000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1080000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
1080000 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1997000 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1096000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2064000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4387000 usd
CY2023Q3 cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-2685000 usd
CY2022Q3 cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-2983000 usd
cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-9521000 usd
cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-9982000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
735000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7285000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12968000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33327000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18251000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
62000 usd
us-gaap Net Income Loss
NetIncomeLoss
-60579000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-738000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15156000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-599000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-39483000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34127000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33527000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86531000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-100062000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49633104 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49633104 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42525855 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42525855 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47355992 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47355992 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42377895 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42377895 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
284412000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
397000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3128000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-7193000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21171000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
259574000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3178000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-17134000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21037000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
224585000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3504000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-15156000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18371000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
194562000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
181280000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4071000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-578000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
161644000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26932000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
189000 usd
CY2023Q2 cmps Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Value Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsValueForfeituresAndExpirations
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
687000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4561000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
717000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
166396000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116615000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
76000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4447000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-738000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
253255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-85932000 usd
us-gaap Net Income Loss
NetIncomeLoss
-60579000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
344000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
234000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
310000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-40000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1820000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3842000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13079000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9810000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1494000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1610000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-12433000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
30141000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1035000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1813000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5825000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
306000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1428000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1571000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-567000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20018000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-687000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1253000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69594000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60149000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
489000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-64000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-489000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
144976000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
189000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
29585000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
778000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
401000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173789000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
401000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
857000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-39879000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104988000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-100116000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
248369000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173231000 usd
cmps Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities Including Initial Adoption
RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption
3675000 usd
cmps Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities Including Initial Adoption
RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilitiesIncludingInitialAdoption
796000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248038000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173076000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
331000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
155000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
248369000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173231000 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
us-gaap Net Income Loss
NetIncomeLoss
-85900000 usd
us-gaap Net Income Loss
NetIncomeLoss
-60600000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347100000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
248000000.0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the prepayment and accrual for research and development expenses, share-based compensation and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
656000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div>
cmps Number Of Geographic Regions
NumberOfGeographicRegions
2 region
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
cmps Research And Development Expenditures Tax Credit Connected Parties Maximum Percentage Of Total Claim
ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim
0.15
CY2022Q3 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
2300000 usd
CY2023Q3 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2023Q3 cmps Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1767000 usd
CY2022Q4 cmps Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1684000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1285000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1284000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4769000 usd
CY2023Q3 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
23424000 usd
CY2022Q4 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
13972000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
156000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2818000 usd
CY2023Q3 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
8744000 usd
CY2022Q4 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
28211000 usd
CY2023Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1371000 usd
CY2022Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1652000 usd
CY2023Q3 cmps Vendor Receivable Current
VendorReceivableCurrent
240000 usd
CY2022Q4 cmps Vendor Receivable Current
VendorReceivableCurrent
0 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2075000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1042000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36010000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47695000 usd
CY2023Q3 cmps Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
5712000 usd
CY2022Q4 cmps Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
0 usd
CY2023Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
166000 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
327000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5878000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5534000 usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
0 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
167000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1177000 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8998000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9325000 usd
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3300000 usd
CY2023Q3 cmps Options Number Of Shares Available For Purchase Percent Of Principal Amount Of Term Loan Advances
OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances
0.025
CY2023Q3 cmps Options Exercisable Number
OptionsExercisableNumber
94222 shares
CY2023Q3 cmps Options Exercisable Fair Value
OptionsExercisableFairValue
700000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2023Q3 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2023Q3 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2023Q3 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
109000 usd
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3103000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
28431000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6572000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
14166000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10687000 usd
CY2023Q3 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1100000 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.55
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M17D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
13013000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2512166 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.78
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
162560 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
487578 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.55
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6954760 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
11406000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3126497 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.44
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10085000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3828263 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
13.98
cmps Share Based Compensation Arrangement By Share Based Payment Award Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm
P8Y11M12D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
1320000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1400000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5500000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.29
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
35000000.0 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
30700000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M3D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M8D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8759
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8140
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8767
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8072
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0434
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0270
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0359
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0215
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
8.88
CY2022Q3 cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
14.41
cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
10.40
cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
14.48
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4447000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3504000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13079000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9810000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33389000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18371000 usd
us-gaap Net Income Loss
NetIncomeLoss
-85932000 usd
us-gaap Net Income Loss
NetIncomeLoss
-60579000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-33389000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33389000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18371000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18371000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85932000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-85932000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60579000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60579000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49633104 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49633104 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42525855 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42525855 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47355992 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47355992 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42377895 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42377895 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23493424 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5279430 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23493424 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5279430 shares
us-gaap Operating Lease Cost
OperatingLeaseCost
1705000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1718000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
247000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
111000 usd
us-gaap Lease Cost
LeaseCost
1952000 usd
us-gaap Lease Cost
LeaseCost
1829000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1689000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1679000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3675000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
796000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0849
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0496
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
547000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2172000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1489000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
220000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
55000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4483000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
382000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4101000 usd

Files In Submission

Name View Source Status
cmps-20230930_cal.xml Edgar Link unprocessable
cmps-20230930_lab.xml Edgar Link unprocessable
0001628280-23-036170-index-headers.html Edgar Link pending
0001628280-23-036170-index.html Edgar Link pending
0001628280-23-036170.txt Edgar Link pending
0001628280-23-036170-xbrl.zip Edgar Link pending
cmps-20230930.htm Edgar Link pending
cmps-20230930.xsd Edgar Link pending
cmps-q3x23xex311ceo302cert.htm Edgar Link pending
cmps-q3x23xex312cfo302cert.htm Edgar Link pending
cmps-q3x23xex321ceoxcfosec.htm Edgar Link pending
ex-102xleaseagreementbetwe.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
cmps-20230930_def.xml Edgar Link unprocessable
cmps-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmps-20230930_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending